Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation
- PMID: 37634135
- DOI: 10.1056/NEJMoa2306037
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation
Abstract
Background: The role of catheter ablation in patients with symptomatic atrial fibrillation and end-stage heart failure is unknown.
Methods: We conducted a single-center, open-label trial in Germany that involved patients with symptomatic atrial fibrillation and end-stage heart failure who were referred for heart transplantation evaluation. Patients were assigned to receive catheter ablation and guideline-directed medical therapy or medical therapy alone. The primary end point was a composite of death from any cause, implantation of a left ventricular assist device, or urgent heart transplantation.
Results: A total of 97 patients were assigned to the ablation group and 97 to the medical-therapy group. The trial was stopped for efficacy by the data and safety monitoring board 1 year after randomization was completed. Catheter ablation was performed in 81 of 97 patients (84%) in the ablation group and in 16 of 97 patients (16%) in the medical-therapy group. After a median follow-up of 18.0 months (interquartile range, 14.6 to 22.6), a primary end-point event had occurred in 8 patients (8%) in the ablation group and in 29 patients (30%) in the medical-therapy group (hazard ratio, 0.24; 95% confidence interval [CI], 0.11 to 0.52; P<0.001). Death from any cause occurred in 6 patients (6%) in the ablation group and in 19 patients (20%) in the medical-therapy group (hazard ratio, 0.29; 95% CI, 0.12 to 0.72). Procedure-related complications occurred in 3 patients in the ablation group and in 1 patient in the medical-therapy group.
Conclusions: Among patients with atrial fibrillation and end-stage heart failure, the combination of catheter ablation and guideline-directed medical therapy was associated with a lower likelihood of a composite of death from any cause, implantation of a left ventricular assist device, or urgent heart transplantation than medical therapy alone. (Funded by Else Kröner-Fresenius-Stiftung; CASTLE-HTx ClinicalTrials.gov number, NCT04649801.).
Copyright © 2023 Massachusetts Medical Society.
Comment in
-
Catheter ablation improves outcomes in patients with AF and end-stage HF.Nat Rev Cardiol. 2023 Nov;20(11):721. doi: 10.1038/s41569-023-00932-9. Nat Rev Cardiol. 2023. PMID: 37697073 No abstract available.
-
In symptomatic AF with end-stage HF, adding catheter ablation to medical therapy improved clinical outcomes at 18 mo.Ann Intern Med. 2023 Dec;176(12):JC137. doi: 10.7326/J23-0096. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048574
-
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.N Engl J Med. 2023 Dec 28;389(26):2495. doi: 10.1056/NEJMc2312887. N Engl J Med. 2023. PMID: 38157509 No abstract available.
-
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.N Engl J Med. 2023 Dec 28;389(26):2495-2496. doi: 10.1056/NEJMc2312887. N Engl J Med. 2023. PMID: 38157510 No abstract available.
-
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. Reply.N Engl J Med. 2023 Dec 28;389(26):2496-2497. doi: 10.1056/NEJMc2312887. N Engl J Med. 2023. PMID: 38157511 No abstract available.